nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-0A7A72AD·Framework v5.10·Pipeline v0.4·Evaluated 02 Nov 2026·OECD: 3.2 Clinical medicine·Subfield: Genetics·Basis: Full text·Type: Randomized controlled trial

Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema

Danny M. Cohn et al.Danny M. Cohn, Padmalal Gurugama, Hilary J Longhurst et al.·2026·New England Journal of Medicine·10.1056/nejmoa2600931 ↗

Primary claim

Among patients with hereditary angioedema due to C1 inhibitor deficiency, a single dose of lonvo-z resulted in a significantly lower rate of hereditary angioedema attacks than placebo from 5 through 28 weeks after infusion.

Well-supported · prespecified randomized comparison with a large effect and consistent secondary efficacy findings
In brief

A single lonvo-z infusion delivers a large placebo-controlled reduction in hereditary angioedema attacks, but short follow-up leaves permanent-edit safety unresolved.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Likely to hold — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

BACKGROUND: Hereditary angioedema is a rare and potentially life-threatening genetic condition characterized by recurrent and debilitating swelling attacks. Lonvoguran ziclumeran (lonvo-z) - an investigational, in vivo gene-editing treatment based on clustered regularly interspaced short palindromic repeats (CRISPR) - is being developed as a single-dose treatment for hereditary angioedema. METHODS: In a phase 3, double-blind trial, we randomly assigned, in a 2:1 ratio, patients who were 16 years of age or older and had hereditary angioedema with C1 inhibitor deficiency to receive a single intravenous infusion of lonvo-z (at a dose of 50 mg) or placebo. The primary end point was the number of investigator-confirmed hereditary angioedema attacks per month (the monthly attack rate) from week 5 through week 28 after infusion. RESULTS: A total of 80 patients underwent randomization; 52 were assigned to receive lonvo-z and 28 to receive placebo. As of February 10, 2026, the median duration of follow-up was 7.5 months (range, 4.9 to 12.8). The least-squares mean monthly attack rate from weeks 5 through 28 was 0.26 (95% confidence interval [CI], 0.15 to 0.45) in the lonvo-z group and 2.10 (95% CI, 1.55 to 2.86) in the placebo group (relative difference, -87%; 95% CI, -93 to -78; P<0.001). Adverse events that occurred during or after infusion of lonvo-z or placebo were reported in 92% and 86% of the patients in the lonvo-z and placebo groups, respectively, from day 1 through week 28. Among the adverse events that occurred during or after infusion and more often in the lonvo-z group than in the placebo group, the most common (occurring in >10% of the patients in the lonvo-z group) included infusion-related reaction, headache, fatigue, back pain, and upper respiratory tract infection. No serious or grade 3 or higher adverse events were reported in the lonvo-z group. CONCLUSIONS: Among patients with hereditary angioedema, a single intravenous infusion of lonvo-z resulted in a significantly lower rate of hereditary angioedema attacks than placebo. (Funded by Intellia Therapeutics; HAELO ClinicalTrials.gov number, NCT06634420.).

Key Claims

Primary finding · Well-supported

Among patients with hereditary angioedema due to C1 inhibitor deficiency, a single dose of lonvo-z resulted in a significantly lower rate of hereditary angioedema attacks than placebo from 5 through 28 weeks after infusion.

Likely to hold — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

prespecified randomized comparison with a large effect and consistent secondary efficacy findings

Discussion, concluding paragraph
Quote verified
Secondary · Supported

Patients in the lonvo-z group had a greater improvement in the AE-QoL total score from baseline to week 28 than those in the placebo group

controlled improvement exceeds the stated clinical threshold, but week-28 arm counts remain unexplained

Results, Key Secondary End Points; Table 2
Quote verified
Secondary · Supported

62% of the patients who received lonvo-z were considered by the investigator to be attack-free from weeks 5 to 28 without the use of long-term prophylaxis.

reported counts support the percentage, but incomplete week-28 observation limits full-window attack-free interpretation

Discussion, first paragraph
Quote verified
Secondary · Supported

No serious or grade 3 or higher adverse events were reported in the lonvo-z group.

systematic reporting supports observed events, but 52 treated patients and short follow-up limit detection of rare or delayed harms

Abstract; Results, Safety; Table 3
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Controlled evidence for a single infusion

The phase 3 comparison moves beyond earlier lonvo-z studies to demonstrate a large reduction in attacks under randomized, blinded placebo control.

↳ Introduction; Results, Primary End Point; Table 2

#methodological rigour

Prespecified analyses and systematic harms collection

The endpoint hierarchy controls formal testing, and the primary model accounts for baseline attack frequency and follow-up duration. Harms reporting includes infusion reactions, liver enzymes, and event severity.

↳ Methods, Statistical Analysis; Results, Safety; Table 3

#positioning

Safety uncertainties receive explicit contextual treatment

The discussion considers immunogenicity, hepatic events in other gene-editing programs, congenital kallikrein deficiency, and off-target effects. Its conclusion retains a potential-treatment framing rather than claiming established long-term safety.

↳ Discussion, safety evidence and concluding paragraphs

Limitations

#methodological rigour

Limited observation for a permanent intervention

The trial includes 80 patients with median follow-up of 7.5 months, and 16 had not reached week 28. These data cannot establish rare or delayed harms or long-term durability.

↳ Results, Patients; Discussion, limitations

#methodological rigour

Infusion reactions create a masking uncertainty

Infusion-related reactions occurred in 62% of lonvo-z recipients versus 18% of placebo recipients. With diary-based attack reporting, the absence of a reported blinding-success assessment leaves uncertainty about masking integrity.

↳ Methods, Clinical Assessment; Results, Safety; Table 3

#reporting

Week twenty-eight denominators remain insufficiently reconciled

Results reports 43 lonvo-z and 21 placebo patients reaching week 28, whereas the AE-QoL footnote reports available data for 44 and 20. The shared total of 64 does not explain the arm-specific difference.

↳ Results, Patients; Table 2 footnote ¶

Does this match your read? Add your assessment ↓

Nabu Commentary

The blinded phase 3 comparison establishes a substantial short-term efficacy advance over the earlier lonvo-z evidence, with attack-rate and quality-of-life outcomes favoring treatment. Stratified randomization, hierarchical testing, follow-up-adjusted modeling, and systematic harms collection support the analysis. The main constraint is the limited observation period for a permanent intervention, compounded by uncertainty about masking when infusion reactions differ markedly between groups. The discussion engages competing safety evidence and links limitations to appropriately bounded conclusions, while the unexplained week-28 AE-QoL arm counts reduce reporting clarity.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
4.3±0.1

Contribution
4.5

The randomized phase 3 comparison advances earlier phase 1–2 evidence by establishing a large short-term efficacy effect under blinded placebo control. The contribution is clearly delineated, but it does not establish long-term durability or delayed-harm risk.

Introduction, prior phase 1–2 evidence; Results, Primary End Point; Discussion
Methodological Rigour
4.2

Stratified randomization, a prespecified endpoint hierarchy, follow-up-adjusted analysis, and systematic harms collection support the controlled efficacy comparison. Incomplete week-28 follow-up and possible masking compromise from infusion reactions leave identifiable execution uncertainties.

Methods, Randomization and Treatment and Statistical Analysis; Results, Patients; Table 3
Reporting
4.4

The paper connects its biological rationale, endpoint hierarchy, and reported effects while distinguishing observed efficacy from unresolved long-term risks. The unexplained difference between week-28 evaluation and AE-QoL availability counts makes secondary-endpoint denominators less readily traceable.

Abstract; Results, Patients and Key Secondary End Points; Table 2 footnote ¶; Discussion
Positioning
4.3

The discussion engages prior prophylaxis evidence, earlier lonvo-z trials, immunogenicity, hepatic events in other editing programs, and off-target uncertainty. Limitations are linked to generalizability and long-term safety, although comparative positioning remains qualitative and masking integrity is not discussed.

Introduction; Discussion, safety evidence and limitations paragraphs

Lower confidence on Methodological Rigour — domain match limited.

Reliability

Caveats4 of 4 checks


Results checkNoted
  • Patients in the lonvo-z group had a greater improvement in the AE-QoL total score from baseline to week 28 than those in the placebo group: "data were available for 44 patients in the lonvo-z group and 20 patients in the placebo group" (Table 2, footnote ¶ (AE-QoL)) vs "A total of 64 patients (43 in the lonvo-z group and 21 in the placebo group) reached at least the week 28 evaluation" (Results, Patients). Comparing the reported arm counts gives 44/20 for AE-QoL availability versus 43/21 for week-28 evaluations, with the same total of 64 but an unexplained arm-specific difference. → Effect on result unclear
Reporting and transparencyClean

Ethics approval, written consent, trial registration, sponsor funding, and conflicts of interest are declared. Referenced external materials could not be independently inspected and do not establish a conduct concern.

Conflict of interest: declared · Ethics approval: declared · Preregistration: declared · Data availability: declared

Reference IntegrityClean

28 of 28 checkable references verified

32 references in manuscript 4 are books, websites or datasets — counted, but not index-checkable

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 02 Nov 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Metabolic and endocrine · Endocrine, metabolic, blood, and immune disorders
Type of advanceEmpirical
Route to useSuggested
AdvanceConsolidates
BeneficiariesCatch-all cause
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

A multinational double-blind placebo-controlled phase 3 trial across 31 sites in 80 randomized patients confirmed the primary efficacy claim against placebo.

From the paper
“These data support the use of lonvo-z as a potential treatment for hereditary angioedema.”

The paper explicitly names a real-world use, a treatment for hereditary angioedema, but names no profession, organisation or setting that would act on it.

Pathway

Regulators would approve lonvo-z and allergy or immunology clinicians would administer one infusion to hereditary angioedema patients, replacing lifelong prophylaxis.

Barrier

The drug remains investigational, with limited follow-up beyond 28 weeks and unresolved long-term safety questions including off-target editing and cardiovascular risk.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks

    Riedl, Farkas, Aygören-Pürsün, et al. · 2024 · Clinical medicine

    Primary claim

    Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.

    Well-supported
    Evidence Score
    4.2±0.2
    Reliability
    No concerns
  2. Efficacy and Safety of Donidalorsen for Hereditary Angioedema

    Riedl, Tachdjian, Lumry, et al. · 2024 · Clinical medicine

    Primary claim

    Donidalorsen at a dose of 80 mg administered subcutaneously every 4 or 8 weeks significantly reduced the hereditary angioedema attack rate

    Supported
    Evidence Score
    4.0±0.1
    Reliability
    Caveats
  3. CRISPR-Based Therapy for Hereditary Angioedema

    Cohn, Gurugama, Magerl, et al. · 2024 · Clinical medicine

    Primary claim

    NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema.

    Tentative
    Evidence Score
    3.6±0.1
    Reliability
    Caveats

How the rubric works →